iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Buy” by Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have earned an average rating of “Buy” from the five analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $120.00.

Several analysts have recently weighed in on IRMD shares. Lake Street Capital restated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Roth Mkm restated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Finally, Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 2,500 shares of the company’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $94.84, for a total value of $237,100.00. Following the completion of the sale, the chief executive officer owned 2,217,500 shares in the company, valued at $210,307,700. This represents a 0.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 40,000 shares of company stock valued at $3,995,700. 36.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On iRadimed

Large investors have recently bought and sold shares of the company. CWM LLC raised its position in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the last quarter. Quarry LP acquired a new position in shares of iRadimed during the 3rd quarter worth $40,000. Farther Finance Advisors LLC increased its holdings in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in iRadimed during the 3rd quarter valued at about $47,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Trading Up 0.1%

Shares of NASDAQ:IRMD opened at $93.54 on Tuesday. The company has a market capitalization of $1.20 billion, a PE ratio of 53.45 and a beta of 1.11. iRadimed has a twelve month low of $50.00 and a twelve month high of $107.90. The firm has a 50 day simple moving average of $99.22 and a 200-day simple moving average of $92.60.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. The business had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts predict that iRadimed will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a $0.20 dividend. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is currently 45.71%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.